UY27688A1 - ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION. - Google Patents

ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION.

Info

Publication number
UY27688A1
UY27688A1 UY27688A UY27688A UY27688A1 UY 27688 A1 UY27688 A1 UY 27688A1 UY 27688 A UY27688 A UY 27688A UY 27688 A UY27688 A UY 27688A UY 27688 A1 UY27688 A1 UY 27688A1
Authority
UY
Uruguay
Prior art keywords
administration
inflammation
agents
treatment
agent
Prior art date
Application number
UY27688A
Other languages
Spanish (es)
Inventor
Julie Taylor
Ted A Yednock
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Publication of UY27688A1 publication Critical patent/UY27688A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4737—C-reactive protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un método para reducir crónicamente una inflamación patológica de un paciente mediante la administración de un agente que se enlaza específicamente a un alfa-4 integrin o bien, se revela un dimer (reductor) que comprende un alfa-4 integrin. El agente proporcionado debe tener una afinidad aglutinante de modo que la administración sea suficiente para suprimir la inflamación patológica, y el agente sea administrado crónicamente para la supresión a largo plazo de la inflamación patológica.A method for chronically reducing a pathological inflammation of a patient by administering an agent that specifically binds to an alpha-4 integrin or, a dimer (reducer) comprising an alpha-4 integrin is disclosed. The agent provided must have a binding affinity so that the administration is sufficient to suppress pathological inflammation, and the agent is chronically administered for the long-term suppression of pathological inflammation.

UY27688A 2002-04-23 2003-02-27 ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION. UY27688A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37450102P 2002-04-23 2002-04-23

Publications (1)

Publication Number Publication Date
UY27688A1 true UY27688A1 (en) 2003-10-31

Family

ID=38813807

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27688A UY27688A1 (en) 2002-04-23 2003-02-27 ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION.

Country Status (2)

Country Link
PE (1) PE20040204A1 (en)
UY (1) UY27688A1 (en)

Also Published As

Publication number Publication date
PE20040204A1 (en) 2004-04-08

Similar Documents

Publication Publication Date Title
PL372306A1 (en) Administration of agents for the treatment of inflammation
AR049518A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING A SILICONE AGENT AND TWO SOLUBILIZED ACTIVE PRINCIPLES
BR0107705A (en) Use of a modified aliquot of blood in a patient to treat congestive heart failure
AR109263A2 (en) COMPOSITION INCLUDING MOXIDECTINE
BRPI0406499A (en) Long-acting insulin to reduce cardiovascular morbidity and mortality in pre-diabetic patients and patients with type 2 diabetes.
BR0212252A (en) Methods to Reduce Hypertension and Heart Failure in a Mammal
BR9906813A (en) Method for administering human aspb28- insulin
EA200101089A1 (en) NEW METHOD OF TREATMENT
HK1064950A1 (en) Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s)
WO2001030802A3 (en) Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies
WO2003000203A3 (en) Chlorotoxin inhibition of cell invasion, cancer metastasis, angiogenesis and tissue remodeling
BR0214196A (en) Method and composition for reducing the growth inhibiting activity of a cancer cell to treat a cancer patient
UY26171A1 (en) PHARMACEUTICAL FORMULATION AND METHOD FOR THE TREATMENT OF LATE APPEARANCE DYSKINESIA
UY27688A1 (en) ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION.
BRPI0410374A (en) pharmaceutical composition comprising valsartan
ATE383863T1 (en) COMBINATION CHEMOTHERAPY
BRPI0414518A (en) pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d and parathyroid hormone derivatives
BR0212989A (en) Methods for neuroprotective treatment using selective inhibitors
MXPA03006477A (en) Method of treatment of type i diabetes.
BR9809376A (en) Pregnan-3-ol-20-ones
UA44393U (en) Method for treatment of patients with the generalized periodontitis
RU2002116408A (en) Method for reperfusion therapy of patients with acute myocardial infarction
FI20010233A0 (en) A method for treating heart failure
ES2193285T3 (en) NITRIC OXIDE INHIBITOR (NO) - SYNTHEASE TO PREVENT TYPE II DIABETES.
MD1568F1 (en) Method of treatment of the burn disease in the burn shock period

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150126